This bill amends the Federal Food, Drug, and Cosmetic Act to add a new type of product identifier: a machine‑readable physical chemical identifier for certain pharmaceutical products. It also revises the law’s definition of verification so that authenticity can be established either by the existing graphic/serialization mechanisms or by these chemical identifiers.
Why it matters: the measure forces the regulated pharmaceutical supply chain to reckon with in‑dose authentication as a complement or alternative to current serialization and packaging‑level traceability. That shifts compliance and manufacturing questions from carton/pack labeling into formulation, production, and testing practices—raising technical, cost, and regulatory hurdles for manufacturers, repackagers, distributors, and regulators.
At a Glance
What It Does
The bill creates an alternative product‑identifier option that is a physical chemical identifier—an intentionally added or intrinsic chemical signature that is machine readable and intended to authenticate a product. It also revises the statutory definition of "verification" to allow authenticity checks that rely on such chemical identifiers, not only on printed or electronic serial codes.
Who It Affects
Manufacturers of controlled substances in solid oral dosage form, contract manufacturers and repackagers, distributors and pharmacies that verify product authenticity, and laboratories and vendors that develop machine‑readable chemical detection and authentication systems are directly affected. FDA and law‑enforcement stakeholders will also need new testing and enforcement approaches.
Why It Matters
By recognizing chemical markers as a lawful means of authentication, the bill opens the door to technologies that operate at the pill level rather than only at the carton or bottle level. That can materially change how compliance programs, serialization systems, and point‑of‑dispense verification are designed and audited across the regulated supply chain.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill modifies existing FDCA definitions and one substantive provision to expand how the pharmaceutical supply chain can demonstrate product authenticity. It does not prescribe a single technology; instead, it creates a statutory category—"physical chemical identifier"—that can serve as a product identifier alongside the current standardized graphic/serialization approach.
The statute requires that the chemical identifier be in or on the product, be machine readable, and be intended to authenticate the product or dosage form.
Operationally, this change reframes verification: where the law previously focused on matching printed or electronic identifiers (standardized numeric identifiers, lot, expiry) to manufacturer records, it now also contemplates authenticity determinations based on detecting a chemical signature. That means supply‑chain actors who today scan barcodes or read serialized labels may need to add chemical‑detection steps or rely on third‑party laboratory validation for certain checks.Practically, manufacturers will face decisions about how to incorporate such identifiers—options could range from microtaggant additives, encoded excipient blends, or surface treatments that produce a detectable chemical fingerprint.
The bill links machine‑readable data carriers for the graphic identifier to international standards bodies, so any dual systems (graphic plus chemical) will need to interoperate with existing serialization standards. Finally, the bill leaves implementation details—testing standards, validation protocols, safety review of ingestible markers, and enforcement mechanics—to downstream rulemaking and practice, creating a significant implementation agenda for FDA and industry.
The Five Things You Need to Know
The bill creates a statutory definition of a "physical chemical identifier" as a unique physical or chemical substance or combination of substances that is in or on a product, is machine readable, and is intended to authenticate the product or its dosage form (new 21 U.S.C. 360eee(14)(B)).
It treats the physical chemical identifier as an alternative form of "product identifier," alongside the existing standardized graphic that must include the standardized numerical identifier, lot number, and expiration date in human‑readable and machine‑readable form.
The statutory definition of "verification" is expanded to include determining authenticity using a physical chemical identifier, not only matching serialized graphic identifiers against manufacturer records (new 21 U.S.C. 360eee(28)).
The scope is limited: the chemical‑identifier approach is tied to controlled substances (as defined in section 102 of the Controlled Substances Act) in solid oral dosage form—so it targets pills and tablets rather than injectables or liquids.
The bill imposes a delayed compliance trigger: the chemical‑identifier requirement applies to products manufactured on or after a date five years after enactment (the amendment to 21 U.S.C. 360eee–1(a)(9)).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This single‑line provision names the measure the "Modern Authentication of Pharmaceuticals Act of 2025." It is formal but signals the bill’s narrow focus on authentication mechanisms rather than broader controlled‑substance policy.
Adds chemical‑identifier requirement for certain products
The amendment inserts a new subparagraph that requires a physical chemical identifier to be included in or on each dose of a product that is a controlled substance in solid oral dosage form, for products manufactured on or after five years from enactment. In practice this moves an authentication obligation from the package level toward the individual dosage unit and creates a hard compliance date manufacturers must budget toward.
Defines 'product identifier' to include a chemical option
The bill revises the statutory definition of "product identifier" to list two mutually available forms: (A) the existing standardized graphic (human‑readable plus a machine‑readable data carrier conforming to international standards) and (B) the new physical chemical identifier. That drafting makes chemical identifiers a statutory equal to serialization, which matters for downstream obligations that reference "product identifier" generically.
Expands 'verification' to cover chemical authentication
This change explicitly authorizes verification methods that determine authenticity by detecting or testing a physical chemical identifier, in addition to the prior test of matching graphic or serialized data to manufacturer records. The practical effect is to permit (and obligate, under compliance expectations) verification workflows that rely on analytical detection rather than only database lookups.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and clinicians seeking safer supply chains — because authentication at the dosage level can make it harder for counterfeit, adulterated, or illicitly diverted controlled pills to reach patients. The bill's aim is to reduce incidents like counterfeit opioid tablets containing fentanyl by enabling pill‑level verification.
- Pharmaceutical manufacturers that invest early in robust authentication technologies — they could gain competitive advantage and reduce counterfeiting risk across markets that adopt similar approaches, and they may be able to differentiate products on safety grounds.
- Regulators and law enforcement — the availability of a statutory pathway for chemical authentication gives FDA and criminal investigators an additional technical tool for tracing and proving counterfeiting or diversion, assuming appropriate testing protocols are adopted.
Who Bears the Cost
- Brand and generic drug manufacturers — they will face formulation, process‑validation, GMP documentation, and stability‑testing costs to incorporate, validate, and disclose any ingestible marker or taggant at scale, and smaller manufacturers may struggle with the investment required.
- Repackagers, contract manufacturers, and upstream suppliers — operations that alter dosage form or source ingredients may need new quality controls and verification steps, complicating white‑labeling and contract production arrangements.
- Dispensers and wholesalers — pharmacies, hospital systems, and distributors may need new detection hardware, software, or relationships with testing labs to perform verification at receipt or point‑of‑dispense, adding capital and operational costs. Regulators (FDA) — without accompanying appropriations or rulemaking resources, FDA will inherit a complex compliance and enforcement burden to define acceptable markers and testing standards.
Key Issues
The Core Tension
The central tension is between the public‑safety benefit of making individual doses harder to counterfeit and the operational, safety, and economic burdens of embedding and validating chemical identifiers in pharmaceuticals: stronger authentication at the pill level can reduce illicit and counterfeit supply, but it requires new chemistry, manufacturing controls, testing infrastructure, and regulatory scrutiny—costs that may fall unevenly across manufacturers and could delay access or increase prices.
The bill creates a high‑level statutory framework but leaves critical implementation details undefined. It does not specify acceptable detection methods, sensitivity thresholds, validation protocols, labeling or disclosure rules for added substances, or how to reconcile marker use with existing drug approval pathways (ANDA/NDA amendments).
Those gaps mean industry and FDA will need to develop technical standards, which can be long, contentious, and expensive to implement.
Another unresolved issue is the safety and regulatory review of ingestible markers. Introducing a new chemical or additive for authentication can trigger toxicology, excipient, or bioavailability questions and could require supplemental approvals or amendments to approved drug applications.
The bill neither sets safety criteria nor allocates authority or funding for that review, creating the risk of delayed compliance or inconsistent approaches across manufacturers and markets.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.